The spotlight on drug costs continues to intensify as Mylan NV joins the ranks of generic and branded Rx firms being investigated by the Department of Justice for their pricing practices.
The firm announced in an 8-K filing that it had received a subpoena on Dec. 3 from the antitrust division...